Yale Cancer Center

Scientists at Yale Cancer Center have discovered new consequences of specific gene mutations that play a role in the development of myelodysplastic syndromes and acute myeloid leukemia.

Researchers at the Yale Cancer Biology Institute have clarified the role of a recurring cancer-associated tumor mutation in glioblastoma multiforme, the most common and most aggressive type of malignant brain tumor.

The National Cancer Institute recently awarded Yale Cancer Center and Yale School of Public Health a new U01 cooperative agreement grant to support research into the impact of diet and exercise for women with ovarian cancer.

A Yale Cancer Center research team has identified novel oncogenic gene fusions in lung and pancreatic cancer, as well as sarcoma. The fusions involve RASGRF1 (an activator of RAS signaling) and promote cellular changes leading to tumor development.

New research led by Yale Cancer Center shows the creation of a next-generation CRISPR-Cas9 “off-switch” and precision tool to aid safe gene editing therapeutics in patients.

Yale Cancer Center held its annual Conclave award ceremony virtually on February 15 to celebrate scientific and caregiver accomplishments in 2021

New research led by Yale Cancer Center scientists shows less than a third of older patients with chronic myeloid leukemia had optimal laboratory monitoring and only two-thirds were adherent to TKI therapy during the first year after diagnosis.

New research led by Yale Cancer Center revealed White patients had significantly more telemedicine visits compared with Black patients for hematologic cancer care during the COVID-19 pandemic.

Ian E. Krop, MD, PhD, has been appointed chief clinical research officer, associate cancer center director for clinical research, and director of the Yale Cancer Center Clinical Trials Office.